GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Insider Ownership

Contineum Therapeutics (Contineum Therapeutics) Insider Ownership : 0.73 % (As of Jun. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Contineum Therapeutics's insider ownership is 0.73%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Contineum Therapeutics's Institutional Ownership is 3.82%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Contineum Therapeutics's Float Percentage Of Total Shares Outstanding is 0.00%.


Contineum Therapeutics Insider Ownership Historical Data

The historical data trend for Contineum Therapeutics's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Insider Ownership Chart

Contineum Therapeutics Historical Data

The historical data trend for Contineum Therapeutics can be seen below:

2024-04-30 2024-05-31
Insider Ownership 0.75 0.73

Contineum Therapeutics Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Contineum Therapeutics (Contineum Therapeutics) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus